Pathways to success targeting CD47-SIRPα

Insights from researchers in the CD47 niche - what do they really think?

February 20, 2018

A look at the controversial CD47-SIRPα landscape

A look at the players in controversial CD47-SIRPα landscape

February 15, 2018

How will the RCC landscape change – who dares, wins?!

A look at the changing face of the RCC landscape, including current and near term trial readouts

February 13, 2018

The death of PD-L1 in urothelial cancer

As inconsistent data abounds, is it time to move on from PD-L1 as a biomarker of response to checkpoint blockade?

February 12, 2018

Future directions in advanced prostate cancer

A look at some new targeted and IO combinations in development for advanced prostate cancer

February 9, 2018

Flying high with the controversial CD47-SIRPα pathway in cancer

A look at biology behind targeting CD47 in cancer and some of the controversies plaguing the space

February 7, 2018

GU18 Preview – Promise and Pitfalls Abound

Highlights and Lowlights from ASCO GU 2018 - what to watch out for.

February 5, 2018

A look at the controversial BMS trial CheckMate-227 in lung cancer

BMS announced that CM-227 hit PFS in lung cancer patients with high tumour mutation load, now what?

February 5, 2018

How Will Adoptive Cell Therapy Crack Solid Tumours?

A look at Dr Malcolm Brenner's work on virus specific T cell therapies

January 31, 2018

Bad news for Bellicum and BPX-501

FDA places Bellicum's BPX-501 on clinical hold - what's the story and what's next?

January 30, 2018

Report on key data in GU Cancers from ASCO-SITC 2018

At ASCO-SITC this weekend there was some compelling new scientific data highlighting subsets of patients who might be eligible for cancer immunotherapy, including novel combination approaches.

January 30, 2018

The STING and Metastasis Controversy Reignited

Expert interview with Dr Glen Barber reignites the controversy over whether STING agonists could cause metastasis in cancer patients.

January 29, 2018

Immune Landscape of Pancreatic Cancer

A look at where we are in pancreatic cancer and how the landscape has evolved of late...

January 25, 2018

A look at an up and coming west coast biotech

A look at the pipeline of the up and coming Seattle biotech, Alpine Immune Sciences

January 22, 2018

Can STING agonists promote cancer metastasis?

Can STING agonists promote cancer metastasis in some patients? That's one of the key questions from new research linking chromosomal instability with tumor metastasis through activation of the cGAS-STING pathway.

January 23, 2018

ASCO GI18 Preview

A look at 8 key abstracts being presented at #GI18 in San Francisco this week.

January 17, 2018

Tears Before Bedtime…

How does positive trials from Roche and Merck impact the 1L NSCLC landscape?

January 16, 2018

How Obsidian could revolutionise CAR T cell therapy in solid tumours

A look at how new approaches in synthetic biology could revolutionise cell therapy in solid tumours

January 10, 2018

JPM18 Healthcare Day 3 Highlights

Commentary on Day 3 at 2018 JP Morgan Healthcare Conference in San Francisco

January 10, 2018

Highlights of JPM18 Healthcare Day 2

Commentary on Day 2 of the 2018 JP Morgan Healthcare Conference in San Francisco

January 9, 2018
San Francisco Trolley Car

Highlights of JPM18 Healthcare Conf Day 1

Commentary on Day 1 of the 2018 JP Morgan Healthcare Conference in San Francisco

January 8, 2018

Key trends in oncology R&D for 2018 – Part 1

New series on Key Trends in Oncology for 2018

January 4, 2018

A competitive threat to CAR T cell therapy in aggressive lymphoma

New approaches that enter a market unexpectedly can disrupt the status quo and push out more severe therapies to later lines of treatment

January 3, 2018

The Future of Multiple Myeloma

A look at key pipeline developments in multiple myeloma through the lens of a global expert in the field

January 2, 2018

ASH17 masterclass with Dr John Leonard on lymphomas

An interview with Dr John Leonard exploring his thoughts on some of the key lymphoma data at #ASH17

December 14, 2017

ASH17 Will MURANO impact the CLL landscape?

As we see new readouts emerge with different doublets and triplets in CLL, how will they impact the treatment landscape?

December 13, 2017
Snow at GWCC

Commentary on ASH17 Day 2 in Atlanta

Commentary on Sunday at 2017 ASH annual meeting in Atlanta

December 10, 2017

ASH17 – Day 1 Highlights and Lowlights

A look at some of the sessions and learnings from the first day at ASH 2017

December 9, 2017

A potential new IO combination for clinical development

People love hearing about new or emerging cancer targets - there's always the hope that one might find something cool that could move the needle and really make a difference...

December 8, 2017

IMpower150 lung cancer trial provides a window to the Future of Immunotherapy

The first phase 3 trial in 1L NSCLC to hit the PFS endpoint is Genentech's IMpower150. What can we learn from this study?

December 7, 2017

SABCS17 Update on CDK4/6 Inhibitors

A look at the latest CDK4/6 inhibitor data including the important phase 3 trial with ribociclib (MONALEESA-7).

December 6, 2017

ASH17 CAR T cell therapy Preview

A look at what's hot in CAR T cell therapies at #ASH17

December 4, 2017

Top 10 #ASH17 abstracts to watch out for

The Mav's key oral abstracts to follow at #ASH17 -- warning this list includes quirky selections!

November 30, 2017

ASH Preview 2 – Developmental Therapeutics

A look at a selection of promising Developmental Therapeutics abstracts from ASH17 - what's in store this year?

November 29, 2017

What can genomics and tumours teach us about cancer drug development?

A look at loss of heterozygosity and what it means for new lung cancer therapies

November 20, 2017

All that you leave behind

Integrated biomarker approaches are beginning to emerge to help researchers segment patients better for appropriate therapy. Here's one approach...

November 16, 2017

Why we should be cautiously optimistic about the cabiralizumab plus nivolumab data in pancreatic cancer

A look at the cabiralizumab plus nivolumab combination in PDAC at SITC over the weekend

November 15, 2017

Can entinostat overcome resistance to pembrolizumab?

A look st Syndax's entinostat and what happens when given in combination with pembrolizumab in melanoma and lung cancer

November 14, 2017

Nektar hits it out of the park at SITC 2017

A look at Nektar's promising IO portfolio and what's next for the up and coming biotech

November 13, 2017

The Stars from Day 2 of SITC17

Ten stars from the clinical presentations on Day 2 of SITC 2017

November 12, 2017

Interview with Dr Stephan Grupp on the JCAR015 ROCKET trial

A CAR T cell therapist's perspective on the Juno JCAR015 ROCKET dataset

November 11, 2017

SITC17 DAY 1 Highlights and Lowlights

A look at some of the main events from the first day at SITC 2017 - including Juno's ROCKET data.

November 10, 2017
National Harbor from Gaylord Hotel

SITC17 – Final Look at what to watch out for

Final SITC17 Preview and a look at key talks now that the abstracts are available.

November 8, 2017

TARGETS17 Gems from the Poster Halls

A look at new targets, molecules and approaches to cancer research from #TARGETS17 in Philly

November 7, 2017

Some simply stunning cancer research for Journal Club

Science Fridays: A look at six key studies recently published on cancer research that BSB readers can learn from.

November 3, 2017

Key Highlights from Day 3 at AACR-NCI-EORTC TARGETS17

Highlights from Day 3 of the AACR-NCI-EORTC Molecular Targets meeting in Philadelphia

October 29, 2017

Highlights from Day 2 AACR-NCI-EORTC #TARGETS17

A look at some of the important data coming out of Day 2 of #Targets17 in Philadelphia

October 28, 2017

Key Highlights From AACR Molecular Targets Day 1

Commentary on Day 1 of 2017 AACR NCI EORTC Molecular Targets and Cancer Therapeutics Conference in Philadelphia

October 27, 2017

SCLC – An in-depth look at ROVA-T and TRINITY

A look at ROVA-T's chances in the upcoming phase 2 TRINITY trial readout

October 25, 2017

A look at the SCLC Landscape and Rova-T

A look at the SCLC landscape including some promising new developments

October 24, 2017


A look at the trials and tribulations for Immune Design's CMB305 and what's the latest in 1L NSCLC

October 20, 2017

Going beyond PD-L1 expression as a immune biomarker

What other approaches might be useful for predicting response (or non-response) to cancer immunotherapies?

October 19, 2017

Update on CD123 and other viable targets in AML

With increasing evidence that CD123 is a suboptimal target in AML, what other approaches might be more useful to consider?

October 17, 2017

SITC 2017 What to Watch for in Late Breaking Posters

A look at some of the LBA posters to be presented at #SITC17 in November

October 16, 2017
National Harbor Maryland

Five key late breakers to watch out for at SITC17

A look at 5 key oral late breakers at #SITC17 and what to expect or watch out for

October 13, 2017

Targeting Natural Killer Cells in Cancer Immunotherapy

Can we address inhibitory factors that dampen NK cells to enhance the anti-cancer effect on tumours?

October 11, 2017

Red and green flags in 1L NSCLC trials

Our latest predictions in 1L NSCLC and what to expect from the upcoming trial readouts in this niche

October 10, 2017

Immunotherapy Possibilities in Pancreatic Cancer

A look at what's different about exceptional responders in PDAC and what can we learn about neoantigen approaches here?

October 5, 2017

The Future of Cancer Vaccines Part 5 – An Interview with Prof George Coukos

A look at the latest developments in cancer immunotherapy in ovarian cancer, with a particular focus on neoepitopes and cancer vaccines.

October 3, 2017

The Future of Cancer Vaccines Part 3 – Interview with Prof Ugur Sahin

A look at Ugur Sahin's BioNTech and personalized mRNA vaccines

September 28, 2017

The Future of Cancer Vaccines Part 2 – interview with Dr Ira Mellman

Genentech have several cancer vaccine collaborations in place, where do they see the future going in this niche?

September 27, 2017

The Future of Cancer Vaccines – An Interview with Dr Cathy Wu

Part 1 of a new mini-series on cancer vaccines. This one covers an update on Neon's neoantigen approach...

September 26, 2017

Hyperprogression – is it real or fake news?

After pseudoprogression, the IO field has moved onto hyperprogression. What is it and why does it matter?

September 25, 2017

How to disrupt the CAR T cell therapy space

Is the CAR T cell therapy space ready for disruption? At least one researcher thinks so. What does this entail?

September 21, 2017

PROSPECTing for nuggets with PROSTVAC in CRPC

A post mortem analysis of the Bavarian Nordic PROSTVAC cancer vaccine trial failure in CRPC

September 15, 2017

Can this novel combination overcome resistance to checkpoint blockade?

An early look at a new IO combination that may help overcome resistance to checkpoint therapy

September 14, 2017

ESMO17 Day 4 Highlights and Lowlights

A look at the last day of ESMO17 with key data on cancer vaccines, checkpoint and targeted therapies to explore

September 12, 2017

ESMO Day 3 Highlights and Lowlights

A roundup of the key trials and targets presented on Sunday at #ESMO17

September 10, 2017

ESMO17 Day 1 Highlights and Lowlights

A look at mostly lung cancer highlights from the first 2 days at #ESMO17

September 9, 2017

ESMO Preview 5 – intriguing small biotech immunotherapies

A look at some of the small biotechs and what they're developing on IO front that looks intriguing at #ESMO17

September 6, 2017

ESMO Preview 4 – Rock around the clock

8 key ImmunoOnc studies being presented at #ESMO17 this month

September 4, 2017

Is CD123 a good target in AML?

A look at what's happening with Cellectis and their clinical trial program with CD19 and CD123 CARs.

August 31, 2017

The dawn of a new beginning for Cellectis?

What does the future hold for Cellectis and allogeneic "off the shelf" CAR T cell therapy?

August 30, 2017

Waseem Qasim Pioneers Allogeneic CAR T Cell Therapy

Gene editing looks set to become entrenched in allogeneic CAR T cell development, so what's new?

August 29, 2017

A man on a Mission to #FinishCancer

Does timing and sequencing of immune agonists impact their effect when given with checkpoint blockade?

August 28, 2017

ESMO17 Preview 3 – A look at HCC and Blueprint’s BLU-554

A look at the changing HCC market and how pipeline agents may (or may not) impact the landscape...

August 24, 2017

August 2017 BSB Journal Club on Breast Cancer

After recent readouts of breast cancer trials at #ASCO17, where do we go next for future combos? Based on recent preclinical research, we have some ideas...

August 22, 2017

A look at CheckMate-214 in 1L metastatic RCC

A look at the interim results from the BMS CheckMate-214 trial in renal cell carcinoma

August 16, 2017

ESMO17 Preview 1 – The IO 5

Top 5 IO oral abstracts to watch out for in Madrid

August 15, 2017

How to revolutionize cancer immunotherapy trials

A look at various factors that can influence cancer immunotherapy trials through the lens of an immunologist

August 10, 2017

Exploring pre-existing immunity in cancer immunotherapy trials

A look at the role of pre-existing immunity in cancer immunotherapy trial readouts at ASCO17

August 8, 2017

Jumpstarting the immune system with synthetic immunity

Jumpstarting the immune system with a synthetic immunity approach - how can we do this?

August 2, 2017

A hidden gem at ASCO17

How can we boost the efficacy of checkpoint therapies? One way is to drive more activated T cells into the tumour.

August 1, 2017

MYSTIC Interim Analysis July 2017 shows PFS Miss

A look at AZN's miss with their IO-IO combination in 1L NSCLC

July 27, 2017

A look at why we get mixed results with phase 3 checkpoint trials

A look at why checkpoint therapy trials might be giving us inconsistent results of late

July 25, 2017

A look at Nektar Therapeutics immunotherapy pipeline

Update on Nektar Therapeutics IO portfolio and a look at their burgeoning autoimmune disorder pipeline

July 24, 2017

Can epigenetic therapy boost cancer immunotherapy?

A look at the intersection of epigenetics and cancer immunotherapy - what can we learn and where are we going in this niche?

July 19, 2017

Predictions in 1L NSCLC trials

A second look at the evolving 1L NSCLC landscape with a focus on MYSTIC and IMpower150

July 17, 2017

Paris Immuno-Oncology Summit 2017

Commentary on 2017 Paris Immuno-Oncology summit organised by European Academy of Tumor Immunology and Miltenyi Biotec

July 10, 2017

Why did Atezolizumab fail in advanced Urothelial Bladder Cancer?

Why did the IMvigor211 phase 3 trial with atezolizumab in UBC fail? BSB spoke to Prof Tom Powles.

June 27, 2017

Can a vaccine make a difference in sarcoma?

What can we learn from the Immune Design data in sarcomas with their NY-ESO-1 vaccine?

June 21, 2017

New developments in sarcoma

What's new in the sarcoma space? Which novel approaches are worth watching out for?

June 20, 2017

A promising IO combo approach to watch out for

Overcoming resistance to monotherapy treatment with checkpoint blockade is crucial for success with IO combos. Here's one potential solution...

June 19, 2017

New IO developments in breast cancer

A look at checkpoint blockade in early stage breast cancer - encouraging or not?

June 14, 2017

Novartis JULIET trial and other CAR-T cell issues

A look at the initial results from the Novartis CTL019 pivotal trial in aggressive lymphoma (JULIET).

June 8, 2017

Trends, Highlights and Lowlights from ASCO 2017

Beyond the incremental improvements seen in clinical trials, what are the new trends emerging from ASCO 2017 that will impact oncology R&D?

June 6, 2017
Chicago River

ASCO 2017 CAR T Cell Therapy Preview

Some intriguing surprises in the CAR T cell therapy abstracts this year...

May 24, 2017
ASCO 2014 Chicago Contemplation

An up and coming area in early oncology R&D

A look at an up and coming niche in cancer research that may turn out to be useful in conjunction with checkpoint blockade

May 22, 2017

5 key abstracts to consider from ASCO 2017

A look at 5 key abstracts that tickled my fancy from #ASCO17; Warning - not all are positive!

May 18, 2017

ASCO 2017 Preview 2 – IDO1 Inhibitors

Update on #ASCO17 data for IDO1 inhibitors in various cancers

May 17, 2017

Things we need to think about ahead of ASCO17

A fireside chat with a leading KOL involved in cancer research on resistance.

May 16, 2017

Can AstraZeneca leapfrog the competition in lung cancer AGAIN?

Durvalumab grabs pole position in unresectable NSCLC amongst IO compounds

May 12, 2017

On Kite’s cerebral edema and Genentech’s IMvigor211 miss

We've been overdue a correction in the irrational exuberance around IO... is this the tip of the iceberg?

May 10, 2017

On Gritstone and neoantigens

A look at a promising biotech in the neoantigen space - what's their approach and how might it fare?

May 4, 2017

Do Exosomes Matter?

With 'liquid biopsies' on the rise, we take a look at another potential candidate that could be useful - exploring exosomes.

May 2, 2017

How do we get cancer immunotherapy to work in Prostate Cancer?

A candid look at new approaches being explored in cold tumours using prostate cancer as an example

May 1, 2017

Can AZN take immuno-oncology to the next level?

Through the keyhole with a look at AZN and MedImmune's IO portfolio

April 25, 2017

What do we know about Resistance to Checkpoints in Lung Cancer?

Expert interview at AACR17 with Dr Julie Brahmer on lung cancer immunotherapy resistance and preview of ASCO17 abstracts

April 20, 2017

Potential of CAR T cell therapy targeting Glioblastoma

Encouraging new developments in GBM with a novel CAR T cell therapy

April 18, 2017

Overcoming Cancer Immunotherapy Resistance

How do we overcome resistance to cancer immunotherapies? Here, we have an in-depth interview with a thought leader in this space.

April 17, 2017

Dan Chen outlines his vision for the Future of Cancer Immunotherapy at AACR17

Dr Daniel Chen from Roche/Genentech shares his vision for the future of cancer immunotherapy at AACR17.

April 13, 2017
AACR17 audience

Five Emerging Cancer Research Trends at AACR17

Five emerging cancer research trends we picked up at AACR17 that you should be aware of.

April 11, 2017

What does atezolizumab TNBC data presented at AACR17 tell us about breast cancer immunotherapy?

Interview with Professor Peter Schmid, Barts Cancer Institute.

April 10, 2017

Corvus CPI-444 Data Disappoints at AACR 2017

Commentary on Tuesday at 2017 AACR annual meeting in Washington DC.

April 5, 2017

A Busy Monday at AACR 2017

Commentary on Monday at the 2017 AACR annual meeting.

April 4, 2017

Sunday at AACR 2017 annual meeting

Commentary on Sunday at the 2017 AACR annual meeting

April 3, 2017

Reflections on Saturday at AACR17

Highlights from Day 1 at AACR17

April 1, 2017

AACR 2017 Preview 10

A look at some of the key sessions featuring checkpoint blockade at the AACR 2017 annual meeting

March 29, 2017

AACR 2017 Preview 9

A comprehensive review of the key abstracts in the CAR T cell therapy niche and hints of the latest emerging trends

March 23, 2017

AACR 2017 Preview 6

A look at a new area of immune-oncology that looks set to be in the consciousness more over the next few years

March 15, 2017

AACR 2017 Preview 4

Overcoming immune suppression in the tumour microenvironment

March 9, 2017

AACR 2017 Preview 2

A look at some recent clinical data and what we can learn from the new data expected at AACR in DC

March 7, 2017

AACR 2017 Preview 1

The first of our strategic and thematic AACR Previews for the 2017 annual meeting is here

March 6, 2017

JCAR015 is dead. Long live JCAR015

After a rocky 2016, what does 2017 hold for Juno as they switch focus from JCAR015 to JCAR017?

March 1, 2017

Novel Way to Improve Checkpoint Inhibitor Efficacy

A look at another surprising factor that might affect efficacy of cancer immunotherapy and checkpoint blockade.

March 1, 2017

A novel immune checkpoint target

After JAK1/2 upregulation and PTEN loss, a third mechanism of resistance to checkpoint blockade has been identified. We discuss the issues around this latest challenge...

February 28, 2017

BMT Tandem Cell Therapy Insights

Insight from BMT Tandem 2017 meeting into latest Cell Therapy data

February 27, 2017
Ira Mellman Dan Chen Authors of Cancer Immunity Cycle

Understanding the Cancer-Immune Set Point

A look at cancer immunity and the new framework for exploring the cancer-immune setpoint.

February 22, 2017

Is 2017 the Year of the Cancer Vaccine?

A look at another approach for turning cold into hot (or warmer) tumours with cancer vaccines.

February 21, 2017

Targeting the tumour environment in Lymphomas

What we learnt at ASH16 on how to better target the tumour microenvironment in lymphoid malignancies.

February 6, 2017

How to improve response rates with targeted therapies in oncology

Exploring clinical trials with targeted therapies, including PARP and ATR inhibitors and combination approaches

February 2, 2017

A manifesto for immuno-oncology research

A draft manifesto for IO in cancer research and what we need to learn

February 1, 2017

ASCO GI17 Gems from the Poster Hall

A look at gems from the #GI17 poster halls or molecules destined for Dog Drug Heaven?

January 27, 2017

New developments in advanced colorectal cancer

A couple of trials at ASCO #GI17 look promising in terms of trial design with encouraging implications for the future in metastatic colorectal cancer.

January 26, 2017

Will nivolumab make an impact in gastric cancer?

Will gastric cancer be one of the next indications for nivolumab?

January 25, 2017

How circulating tumor DNA could change cancer treatment

SABCS16 expert interview on the potential of circulating tumor DNA to change the treatment of cancer.

January 16, 2017

Can we expect more surprises in 1L NSCLC?

A look at the how several major phase 3 trial readouts will affect the 1L NSCLC landscape

January 18, 2017
View of Cambridge and Charles River

Does Neon Therapeutics lead the Neoantigen field?

Update on Neon Tx as they move into commercial new product development with their neoantigen platform.

January 13, 2017
Dr Leisha Emens SABCS16

Advances in Breast Cancer Immunotherapy

Second in our series of expert interviews from the 2016 San Antonio Breast Cancer Symposium features Dr Leisha Emens

January 13, 2017
SF Streetcar at Pine St

JPM17 Healthcare Conference Day 3 Highlights

Commentary on Wednesday at JPM17 in San Francisco

January 11, 2017
San Francisco Streetcar in Rain

Highlights of JPM17 Healthcare Conference Day 2

Commentary on Day 2 of the 2017 JP Morgan Healthcare Conference in San Francisco

January 10, 2017
San Francisco Streetcar

Highlights of JPM17 Healthcare Conference Day 1

Commentary around some of the corporate presentations at Day 1 of the 2017 JP Morgan Healthcare conference in San Francisco.

January 9, 2017

The future of CAR T cells in pediatric ALL

Interview with Dr Stephan Grupp on the data he presented at ASH16 and what the future may hold for CAR T cell therapy in pediatric ALL

January 9, 2017

The future of our cancer research business

A look at the emerging trends we can expect in 2017 for cancer research

January 3, 2017

LeonardList showcases 10 Lymphoma Abstracts at ASH16

#LeonardList showcases 10 Lymphoma Abstracts at ASH16

December 19, 2016

Post ASH16 Reader Q+A on CAR T cell therapies

We answer more questions on CAR T cell therapies and ADCs in acute leukemias from ASH

December 16, 2016
The Alamo, San Antonio TX

Emerging Trends from SABCS16 in San Antonio

3 trends from SABCS16 that you may hear more about

December 15, 2016

ASH16 Update on BCMA CAR T cell therapies

A look at the new various developments in CAR Therapies targeting BCMA in multiple myeloma

December 14, 2016
Pedicab at ASH16 in San Diego

Highlights of ASH 2016 Part 2

We answer several critical questions that readers have sent in based on the CAR T cell data at ASH this week.

December 8, 2016
Downtown San Diego during ASH 2016

7 Things I Learned at #ASH16

Highlights (Part 1) from 2016 ASH Annual Meeting in San Diego - 7 initial impressions

December 6, 2016

ENA 2016 Immunotherapy Symposium Highlights

Highlights from the Charles River Immunotherapy Symposium in Munich, 2016

November 29, 2016
ASH15 Late Breaker Session

ASH16 Super Friday Preview

If you have plans to be in San Diego for #ASH16 what should you attend on Friday?

November 28, 2016

Juno plays Russian Roulette with JCAR015

A most unfortunate follow-up to the ongoing safety issues with Juno's JCAR015 and neurotoxicity in the run-up to #ASH16

November 23, 2016

SITC 2016 Can Nektar Boost Checkpoint Performance

Without effector T cells in the tumour, checkpoints won't work. So how do we attract more in? Here's one way to do it...

November 16, 2016

SITC 2016 New Immunotherapy Drug Development

A look at new ways to boost checkpoint therapy performance including agents in development from small biotechs

November 17, 2016

SITC 2016 Update on the Competitive Urothelial Cancer Market

Update on important new data in urothelial cancers and how the landscape is moving quickly

November 15, 2016
National Harbor Maryland

Red Flags in SITC Lirilumab plus Nivolumab Head and Neck Cancer Data

Does adding lirilumab to nivolumab move the needle in relapsed SCCHN?

November 14, 2016

ASH16 Preview on Acute Myeloid Leukemia AML

An in-depth review of what to expect from AML new product development in San Diego

November 11, 2016

ASH16 Preview of CAR T Cell Therapies

What To Watch Out For in CAR T Cell Therapies at ASH in San Diego in December 2016

November 7, 2016

ASH16 Abstracts are out! So What’s Hot at ASH16? My Initial Impressions

Initial impressions of abstracts for ASH16 in San Diego

November 3, 2016

Promising new combos in cancer research pipelines

Four more combination trials of interest in cancer research that may be worth watching out for

November 2, 2016

ESMO16 Gems from the Poster Halls Part 2

Four pretty cool approaches to combination cancer immunotherapy stood out at #ESMO16 in Copenhagen...

November 1, 2016

Glycomics The Third Language of Life

How will glycomics impact cancer research? Some interesting new developments are emerging in this field

October 27, 2016

Insights from biomarkers in ovarian cancer

Can biomarkers help us improve clinical trial outcomes?

October 25, 2016

New Directions in Advanced Lung Cancer

Yesterday saw the FDA approval of atezolizumab (Tecentriq) for the second-line treatment of metastatic…

October 19, 2016

ESMO16 Day 3 Daily Digest

Commentary on Sunday at ESMO16 with a focus on the lung cancer data in the Presidential Symposium

October 10, 2016

ESMO16 Congress Day 1 Digest

Commentary on Day 1 at ESMO 2016 Congress in Copenhagen.

October 7, 2016

How do you calculate Immunoscore? A tour of HalioDx

Audio Slideshow tour of HalioDx lab that shows how digital pathology is used to calculate Immunoscore an immune based colon cancer assay

October 3, 2016

Corvus moves fast to target tumor microenvironment and improve checkpoint responses

Corvus Pharmaceuticals accelerates development of A2A receptor antagonist CPI-444 that could improve checkpoint responses.

September 26, 2016
Dr Eric Pamer presenting at CIML40

Manipulating the Microbiota to Improve Clinical Outcomes. An interview with Eric Pamer

Interview with Dr Eric Pamer on impact of the microbiota on the innate and adaptive immune systems and future directions.

September 28, 2016

Targeting Natural Killer Cells in AML

New research shows potential of cell therapy with allogeneic memory-like natural killer NK cells in AML.

September 27, 2016
Professor Ton Schumacher at CIML40

Is Targeting Neoantigens the Next Frontier in Cancer Immunotherapy?

Interview with Prof Ton Schumacher at scientific meeting to celebrate 40 years of Centre d’Immunologie de Marseille-Luminy (CIML).

September 22, 2016

François Romagné Accelerates Cancer Immunotherapy Innovation in Marseille

Interview with Professor François Romagné, Scientific Director of MI-mAbs, an immuno-oncology drug discovery venture in the Marseille Immunopôle cluster.

September 21, 2016

Innate Pharma at an Inflexion Point. An interview with CEO Hervé Brailly

Interview with Innate Pharma CEO Dr Hervé Brailly on clinical trial readouts expected and his vision for company

September 20, 2016

Why target the Innate Immune system? An interview with Eric Vivier

Professor Eric Vivier is Director of the Centre d’Immunologie de Marseille-Luminy and a co-founder of Innate Pharma and the Marseille Immunopôle. He is a leading researcher in the field of innate immunity.

September 19, 2016

HalioDX CEO Vincent Fert outlines commercial strategy for Immunoscore in US and Europe

Interview with HalioDx CEO Vincent Fert on commercial strategy for Immunoscore diagnostic test.

September 14, 2016

What’s Hot in Ovarian Cancer at ESMO16?

A look at 9 key abstracts in ovarian cancer at #ESMO16 and what to expect

September 8, 2016

ESMO16 What’s Hot in Head and Neck Cancer?

What can we expect in Head & Neck cancer at #ESMO16 in Copenhagen?

September 7, 2016

ESMO16 Preview on Late Breaking Abstracts in Lung Cancer

A look at what to expect from the lung cancer late breakers at #ESMO16 - are there any surprises or controversies?

September 6, 2016

August Journal Club – Cancer Immunotherapy

Launch of the BSB Journal Club - this inaugural edition explores T cell dysfunction and exhaustion

August 25, 2016

Modelling the Tumour Microenvironment

Interview with Prof Fran Balkwill from Barts Cancer Institute on 3D modelling of the tumor microenvironment in ovarian cancer

August 22, 2016

PsiOxus is a cancer immunotherapy company to watch – Part 2 of an interview with CEO John Beadle

Part 2 of interview with PsiOxus Therapeutics CEO Dr John Beadle discusses corporate strategy and challenges faced by an emerging biotech company.

August 17, 2016

Can PsiOxus become a world leading immuno-oncolytic virus company?

An innovative and promising approach to cancer immunotherapy using adenoviruses to deliver multiple warheads to tumours

August 16, 2016

Beyond T-VEC – a look at oncolytic viral immunotherapy

A primer on the oncolytics viral therapy landscape - beyond T-VEC

August 15, 2016

Can neoantigen vaccines make a difference in cancer research?

This is the second in our mini-series on neoantigens and looks at whether neoantigen based cancer vaccines can make a difference in the treatment of solid tumors.

August 10, 2016

NEON shines the light on Neoantigen targeted Cancer Immunotherapy

Cary Pfeffer of Third Rock Ventures describes how a novel neoantigen vaccine in academia transitioned into a commercial company with exciting prospects...

August 11, 2016

What are neoantigens and why do they matter in cancer immunotherapy?

A primer on neoantigens and their importance in cancer research

August 9, 2016

Detailed thoughts on BMS CheckMate–026 1L trial in NSCLC

The BMS CheckMate-026 trial in 1L NSCLC did not meet it's primary endpoint. What can we learn from the failure?

August 5, 2016

New developments in allogeneic cellular therapies

Collaborations in the adoptive cell therapy space have now branched out from autologous to allogeneic products. What's the skinny?

August 5, 2016

What’s new on emerging resistance to cancer immunotherapy?

What factors contribute to resistance with checkpoint blockade and how can this be overcome?

August 4, 2016

Biotech Mailbag – Jounce & the CAR T Race to Market

July Reader Q&A - thoughts on Jounce, Celgene, BMS, J&J and CAR T cell therapies...

July 27, 2016

The changing face of the SCCHN landscape

A example of how different targeted therapy and immunotherapy combinations could be both useful and different from what we've seen before

July 12, 2016

JUNO setback by Patient Deaths due to CAR T Cell Neurotoxicity

Juno ROCKET trial put on clinical hold following 3 death due to cerebral edema. What's the skinny?

July 7, 2016

Can epigenetics play a role in immunomodulation?

Will priming the tumour microenvironment with epigenetic therapies such as HDACs lead to enhanced activity with subsequent immunotherapy?

July 7, 2016

One Step Beyond

With so many new anti-cancer agents, including immunotherapies, emerging in company pipelines, this means that we could see the evolution of important therapy sequences... going beyond combinations.

July 5, 2016

Xencor and Novartis storm the hematologic bispecific market

The oncology bispecific market is heating up with J&J collaborating with Macrogenics and Novartis with Xencor. We discuss the skinny...

June 28, 2016

The potential downside of cancer immunotherapy

We've seen some wonderful responses with checkpoint blockade and cancer immunotherapies, but there are some downsides that need to be considered.

June 27, 2016

How to turn a cold tumour into a hot one

Can we turn a cold tumour into a hot one where some patients can respond to therapy?

June 23, 2016

Checkpoint blockade in MSI High cancers

Update on ASCO checkpoint blockade data for colorectal and other MSI-High cancers

June 22, 2016

Immunoscore validated as an important biomarker for colon cancer

An easy to use new biomarker emerges to help oncologists select colon cancer patients for cancer immunotherapies.

June 20, 2016

Reader Mailbag – TCR T cell Gene Editing in Multiple Myeloma

Gene editing is coming to the US CAR T cell space - what's happening and what will the impact be?

June 17, 2016

Beyond PD-L1 Immunotherapy Biomarkers

Can we find and use several biomarkers to triangulate responders and non-responders?

June 16, 2016

Urothelial Cancer Immunotherapy is a Competitive Landscape

A look at the increasingly competitive metastatic urothelial carcinoma landscape

June 15, 2016

Contemplations on ASCO Lung Cancer Data with Dr Stephen Liu

What to make of the various combination trials presented at ASCO 2016?

June 13, 2016

5 Important and Emerging Trends from ASCO 2016

A number of points of strategic importance fell out of the ASCO data dump. What are they and why do they matter?

June 9, 2016

ASCO 2016 Monday Blog #ASCO16

Commentary from Monday at ASCO 2016 American Society of Clinical Oncology annual meeting in Chicago

June 6, 2016

BMS Ipilimumab prostate cancer immunotherapy trial fails but where is the data?

Prior to chemotherapy men with advanced prostate cancer did not live longer if they received ipilimumab compared to just receiving placebo. The phase 3 trial was a failure.

June 5, 2016

ASCO 2016 Sunday Blog #ASCO16

Top-line commentary from Sunday at ASCO 2016 annual meeting.

June 5, 2016
Chicago River

ASCO 2016 Chicago Saturday Blog #ASCO16

Top-line commentary from Saturday at ASCO 2016 annual meeting.

June 4, 2016

What we learnt at AACR about Aduro ADU-S100

Can we safely combine a STING agonist with a checkpoint inhibitor to generate more effectiveness in melanoma and lymphomas? We asked experts at AACR what they really thought...

May 25, 2016

Statistical Challenges of Immunotherapy Clinical Trial Design

What can we learn about clinical trial design from immunotherapy combinations?

May 23, 2016

Drug Discovery Targets Cancer Vulnerabilities

Commentary from the AACR Precision Medicine Conference in Miami on Targeting the Vulnerabilities of Cancer.

May 20, 2016

George Coukos Drives Novel Ovarian Cancer Immunotherapies Forward

How can we improve T cell trafficking in ovarian cancer? Professor Coukos highlights numerous ways this could be achieved!

May 16, 2016

Is APRIL an exciting new target in Multiple Myeloma?

A look at the BCMA/APRIL landscape in multiple myeloma - this is rapidly becoming a competitive target

May 11, 2016

Targeting OX40 in advanced cancers – Part 2

Beyond checkpoint blockade, companies are now exploring what happens when you combine them with immune agonists such as OX40. Here we explore an industry perspective.

May 10, 2016

AACR Cancer Immunotherapy Insights from Dr Bernard Fox

A wide ranging discussion about how to light the fires in non-immunogenic or cold tumours - OX40, STING, vaccines and more discussed!

May 9, 2016

Can chemotherapy improve checkpoint blockade in advanced colorectal cancer?

Can we safely and effectively add a checkpoint inhibitor to standard chemotherapy and VEGF inhibition? Early proof of concept in patients with metastatic colorectal cancer.

May 4, 2016

Breaking the Immunology Rules – an interview with Dr Michel Sadelain on how CAR T cell therapy will crack solid tumors

At the recent AACR meeting, Dr Michel Sadelain gave a presentation on turbocharged CAR T cells, and shared some of his ideas on how to move the field forward.

May 5, 2016

Controversy: Is Chemotherapy Immunotherapy?

Chemotherapy can have a potentiating effect on cancer immunotherapy. The positive effects may surprise some readers...

May 3, 2016

7 Significant Things I Learned at AACR16 That You Don’t Want to Ignore

What were the major learning points from AACR that will make an impact over the next 1-2 years? Chhhhanges are afoot...

May 2, 2016

Thunderbirds are GO!

Season 2 of the Novel Targets has launched, plus the eagerly awaited April Readers Q&A Mailbag

April 29, 2016

AACR 2016 New Orleans Day 4 Blog

Commentary on Tuesday sessions at AACR 2016 annual meeting

April 19, 2016

AACR 2016 New Orleans Day 3 Blog

Commentary on Monday at AACR 2016 annual meeting

April 18, 2016

AACR 2016 New Orleans Day 2 Blog

Commentary from Sunday at 2016 AACR annual meeting

April 17, 2016

AACR 2016 New Orleans Day 1 Blog

Commentary on Day 1 of AACR 2016 annual meeting in New Orleans.

April 16, 2016

Osimertinib front-line data wows European Lung 2016

First-line data for AstraZeneca’s ($AZN) third generation EGFR inhibitor osimertinib (Tagrisso) impresses at the 2016 European Lung Cancer Conference in Geneva.

April 14, 2016

AACR 2016 CD40 Cancer Immunotherapy

In this preview of AACR 2016, we're looking at the CD40 landscape, some of the new companies that have entered the scene and what presentations to look out for at AACR 2016 (and why they matter).

April 8, 2016

OX40 immune agonists at AACR 2016

Today post is on OX40 (CD134) as a novel immuno-target and what the OX40 cancer immunotherapy landscape looks like.

April 7, 2016

AACR 2016 GITR Cancer Immunotherapy

There are now several agonist antibodies in development and entering the clinic that seek to activate GITR, and new data is expected at AACR 2016.

April 6, 2016

AACR 2016 Cancer Immunotherapy Targeting IDO1 TDO

This post looks at some of the data at AACR 2016 for cancer immunotherapies that target IDO1 and TDO and their downstream effectors.

April 5, 2016

AACR 2016 A Preview of anti TIM-3 and LAG-3 Checkpoints

A look at alternative checkpoint inhibitors, anti-TIM-3 and LAG-3 compounds in early development at AACR

April 1, 2016

Beyond Blinatumomab – Update on Bispecific T cell Engagers

In this post I've taken a close look at one cancer immunotherapy approach with a lot of data at AACR - bispecific T cell engagers.

March 31, 2016

Future of Cancer Immunotherapy

Commentary on some of the latest cancer immunotherapy papers

March 29, 2016

Top 10 Abstracts at AACR 2016

Pick of 10 abstracts at AACR 2016 annual meeting in New Orleans that may answer critical cancer research questions

March 17, 2016

What’s Hot at AACR 2016? Annual Meeting Preview 1

Cancer Immunotherapy dominates AACR 2016 annual meeting in New Orleans.

March 16, 2016

Gems from the EBCC10 Poster Hall

Review of 4 noteworthy posters at the 2016 European Breast Cancer Conference in Amsterdam organised by European Cancer Organisation ECCO

March 10, 2016

Trends in Haplo transplants impact Bellicum

Trends in Haplo stem cell transplants may impact Bellicum Pharmaceuticals adjunct T Cell therapy BPX–501

March 9, 2016

Is TIM–3 the next important checkpoint target?

Could immune resistance be reversed or prevented by the addition of appropriate checkpoint blockade? Which ones matter though, that is the critical question?

March 3, 2016

Could a Novel Cell Therapy replace CAR T Cell Therapy?

Interview at BMT Tandem 2016 about a novel cell therapy that could compete with or replace CAR T cell therapy

March 1, 2016

Are checkpoints playing with fire?

Commentary on presentation by Dr Philippe Armand at BMT Tandem meeting on “Checkpoint Blockade in SCT, Data & Hope, Promise & Peril”

February 25, 2016

Optimizing CD19 CAR T Cell Therapy

Interview with Dr Michael Jensen on CD19 CAR T Cell Therapy

February 23, 2016

Challenges and Opportunities of CAR T Cell Therapy in CLL

Interview at BMT Tandem 2016 with Dr David Porter U Penn on CD19 targeted CAR T cell therapy in CLL

February 19, 2016

What’s hot at BMT Tandem 2016 in Honolulu?

Preview of noteworthy sessions at 2016 BMT Tandem meeting in Honolulu, Hawaii

February 17, 2016

The Next Big Wave in Multiple Myeloma

How do we decide how to incorporate the newly approved drugs in Multiple Myeloma and what's the next wave of therapies we can expect to see evolve?

February 11, 2016

What’s driving the GvHD Landscape? #BMTTandem16

What are some of the strategic trends and drivers in the Graft versus Host Disease (GvHD) space at #BMTTandem16?

February 9, 2016

Will Unum’s approach take the CAR T cell therapy market by storm?

Unum have developed a completely different approach to traditional CAR T cell therapies. Will they make an impact in patients?

February 4, 2016

Immunotherapy for Lymphoma using T cells Targeting Multiple Tumor-Associated Antigens

A novel cell therapy approach uses T cells targeting multiple tumor-associated antigens.

February 3, 2016

Update on Targeted therapies and Immunotherapies in Gastric Cancer

Who will move the needle in gastric and oesophageal cancers - targeted therapies or checkpoint immunoherapies?

January 27, 2016

Will pembrolizumab extend its activity in GI cancers?

Will checkpoint blockade be effective in multiple GI cancers and if so, why?

January 25, 2016

Why didn’t Ipilimumab plus Chemo work in Metastatic Urothelial Cancer?

A trial of gemcitabine plus cisplatin plus ipilimumab in patients with metastatic urothelial cancer failed to meet it's primary endpoint.

January 22, 2016

Day 3 Highlights from JP Morgan Healthcare Conference #JPM16

Commentary on Wednesday corporate presentations at 2016 JP Morgan Healthcare conference in San Francisco

January 13, 2016

Highlights of #JPM16 Healthcare Conference Day 2

Commentary on some of the presentations at Day 2 of JP Morgan Healthcare conference in San Francisco.

January 12, 2016

Highlights of #JPM16 Healthcare Conference Day 1

Commentary around some of the corporate presentations at Day 1 of the 2016 JP Morgan Healthcare conference in San Francisco.

January 11, 2016

New Horizons in CLL Treatment

ASH 2015 interview with Dr Ian Flinn, Director of the Blood Cancer Research Program at the Sarah Cannon Research Institute.

January 5, 2016

Understanding the Cellectis UCART19 Case Report – Part 2 of an Interview with Prof Waseem Qasim

Part 2 of ASH 2015 interview with Prof Waseem Qasim (GOSH) on the first in man gene edited allogeneic CAR T cell therapy.

December 16, 2015

Potential of Gene Editing – Part 1 of Interview with Prof Waseem Qasim

Part 1 of an interview with Prof Waseem Qasim.

December 15, 2015

Checkpoint therapy update in metastatic breast cancer

Adding chemotherapy or an ADC boosts the immunogenic effects prior to checkpoint therapy in metastatic breast cancers

December 11, 2015

Highlights from Plenary Sunday at #ASH15

Commentary on Plenary Sunday at the 2015 ASH annual meeting in Orlando.

December 6, 2015

Highlights from Saturday at ASH 2015 Annual Meeting #ASH15

Commentary on Saturday at ASH15

December 5, 2015

Future of Cancer Immunotherapy Biomarkers

Where is the field of immune biomarkers going beyond PD-L1 in the next few years?

November 27, 2015

ASH15 Preview Checkpoints in classical Hodgkin Lymphoma

Checkpoints in classical Hodgkins Lymphoma - how is the data holding up one year on?

November 25, 2015

Exploring the Potential of Therapeutic Cancer Vaccines

At the recent Society for Immunotherapy of Cancer (SITC) annual meeting, Dr Chris Heery presented a poster on the results of a phase 1 clinical trial to evaluate the safety and tolerability of a therapeutic vaccine targeting brachyury.

November 23, 2015

Q&A on hot topics in CAR T cell therapies

Our latest Q&A based on reader questions - In the Hot Spot: On CAR T cell therapies

November 18, 2015

Novel Immunotherapies and Combinations

Interview with Dr Mario Sznol on Novel Immunotherapies and Combinations

November 17, 2015

Gut Bacteria Impact Checkpoint Inhibitor efficacy

Dr Tom Gajewski (University of Chicago) talks about work from his lab that shows the gut microbiota can impact the efficacy of checkpoint inhibitors.

November 16, 2015

Strategies to overcome CAR T cell therapy resistance

Interview with a leading expert on strategies to overcome CAR T Cell Therapy Resistance

November 12, 2015

How long do we need to give a checkpoint inhibitor for?

At SITC 2015, we heard a tremendous amount of data, but a fresh controversy emerged regarding checkpoint inhibition...

November 11, 2015

Do Cellectis CAR T Cells Really Work?

Expert opinion on First Clinical Application of TALEN Engineered Universal CAR19 T Cells in B-ALL

November 10, 2015

Mixed results with Macrogenics enoblituzumab at SITC

Enoblituzumab is an immune stimulant that targets B7-H3 leading to more T cells.

November 7, 2015

Did the epacadostat combo data disappoint at SITC?

Is Incyte's epacadostat (IDO1 inhibitor) ready for prime time?

November 7, 2015

SITC 2015 – what did we learn from the cancer immunotherapy workshops?

Review of the highlights from the SITC 2015 pre-meeting workshops

November 5, 2015

What IS Hot at ASH 2015 in Orlando? #ASH15 abstracts – Preview 1

Most of the abstracts for the 2015 annual meeting of the American Society of Hematology (ASH) have just gone online. This is a quick initial preview of a few that caught my attention in the immunotherapy space.

November 5, 2015

SITC 2015 International Cancer Immunotherapy Symposium

Commentary on the International Cancer Immunotherapy Symposium held at SITC 2015

November 4, 2015

Preview of SITC 2015 Cancer Immunotherapy Meeting

Preview of what's hot at the 2015 Society for Immunotherapy of Cancer (SITC) annual meeting at National Harbor, MD.

November 3, 2015

CD40 as a Cancer Immunotherapy Target

Companies in the ImmunoOncology space are looking at ways to improve responses with checkpoint inhibitors. Adding an immune agonist is one way to do this.

November 3, 2015

How do we boost the effectiveness of checkpoint inhibitors?

A primer on immunocytokines in cancer immunotherapy with a focus on Roche's CEA-IL2v as a example.

November 2, 2015

Immunosurveillance, Immunoscore & Personalized Cancer Immunotherapy – an interview with Jérôme Galon

Interview with Dr Jérôme Galon on Immunosurveillance, Immunoscore and Personalized Cancer Immunotherapy.

October 30, 2015

What’s Hot at AACR #Targets15 in Boston?

Preview of the key topics coming up at the AACR-NCI-EORTC Molecular Targets meeting in Boston, including Pasi Janne's interesting data on T790M negative NSCLC...

October 27, 2015

Controversies in lung cancer immunotherapy

Should we be using the PDL1 antibody assay to screen patients for therapy with anti-PD1 and PD-L1 checkpoint inhibitors or? How useful is the test? The debate is heating up!

October 26, 2015

Why combine radiation with cancer immunotherapy?

Radiation has the potential to generate an immune response that may lead to an abscopal effect when combined with a checkpoint inhibitor.

October 21, 2015

Is Combining a checkpoint plus an EGFR inhibitor a risky combination?

Will an increase in ILD cases scupper the AZD9291 plus durvalumab combination study in lung cancer? Will there be an advantage for Clovis or not?

October 13, 2015

Where are the breakthroughs coming in Soft Tissue Sarcoma?

Interview at ECC 2015 with Dr George Demetri on new developments in Soft Tissue Sarcoma

October 6, 2015

Potential of Checkpoint Inhibitors in Ovarian Cancer

Interview with Dr Nora Disis about the phase 1b trial results for avelumab in ovarian cancer and the challenges of developing these agents in non-hypermutated tumour types

October 5, 2015

What’s hot at Day 3 of European Cancer Congress?

Commentary on Day 3 of the European Cancer Congress in Vienna

September 28, 2015

ECC Day 2 Highlights – Checkpoints in Lung and Bladder Cancer

Commentary on Day 2 of the European Cancer Congress in Vienna

September 27, 2015

ECC Day 1 Highlights – the battle for Advanced Renal Cell Carcinoma

Highlights from Day 1 of the ECC 2015 (ECCO) meeting in Vienna

September 25, 2015

Novel Targets Podcast 6 – Immune Agonists

What happens when we literally step on the gas with immune agonists?

September 24, 2015

Checkpoint inhibition: targeting TIM-3

T cell immunoglobulin and mucin domain-containing molecule-3 (TIM-3) is widely expressed on immune cells. What's the potential for a TIM-3 checkpoint inhibitor?

September 17, 2015

What’s hot at the AACR International Cancer Immunotherapy Conference?

Review of noteworthy abstracts at CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference in New York

September 16, 2015
Dr Holbrook Kohrt

Holbrook Kohrt Leads the Way in Targeting CD137

Holbrook Kohrt is a Stanford medical oncologist and clinical researcher who is leading the way in cancer immunotherapy combination strategies targeting CD137 (4-1BB).

September 15, 2015

Immunocore ImmTAC TCR platform offers combination promise

Immunocore is an immuno-oncology company with an innovative approach to targeting T Cell Receptors (TCR) using their proprietary ImmTAC (Immune mobilising monoclonal TCRs against cancer) technology platform.

September 14, 2015

ECC Vienna Preview 2 Oral Presentations

What's hot at ECCO 2015 in the oral sessions? An in-depth preview of what we can expect to hear about in Vienna...

September 10, 2015

ECC Vienna Preview 1 Late Breaking Abstracts

What's hot in the 2015 ECCO late breaking abstracts in Vienna? Find out here...

September 8, 2015

Atezolizumab PDL1 Checkpoint Inhibitor will change Bladder Cancer Treatment

Atezolizumab is expected to change the standard of care for the treatment of metastatic urothelial bladder cancer

September 3, 2015

Adoptive Cell Therapies – an interview with Dr Carl June

Dr Carl June on progress of CAR T cell therapies in CLL, myeloma and solid tumours

August 14, 2015

Adoptive Cell Therapy: An Interview with Dr Steven Rosenberg

We know that TILs can be effective in advanced melanoma, but what about common epithelial solid tumours? Can it work in these cancers too? Find out from Dr Rosenberg's latest work what's happening...

August 12, 2015

Oncolytic viruses – are they ready for prime time?

Oncolytic viruses are fast becoming a hot new area in cancer research but who are the players and where is this field going?

August 6, 2015

Will targeting NY-ESO-1 prime the immune system in cancer?

Exploring NY-ESO-1 as a valid target in sarcoma, multiple myeloma and metastatic melanoma...

August 3, 2015

BMS and Exelixis announce new renal cell cancer data

Will checkpoint inhibitors make their mark in renal cell carcinoma and how will they be integrated into a treatment paradigm dominated by VEGF inhibitors?

July 22, 2015

Novel Targets Podcast: Non-inflamed Tumours

Can we find new ways to target prostate cancer and other non-immunogenic tumours with immunotherapies? The answer may surprise...

July 21, 2015

AstraZeneca take a punt on immuno-oncology

Interview with Dr Rob Iannone of AstraZeneca on their IO pipeline

July 15, 2015
Dr William Pao Roche

Do you need a CAR T Cell Therapy to be a Global Cancer Immunotherapy Company?

Interview with Dr William Pao on the Roche antibody based cancer immunotherapy strategy.

July 1, 2015

Juno and Celgene’s unexpected CAR-T cell and TCR collaboration

Editas presented some elegant work using their gene editing technology with CRISPR/Cas9 to modify T cells at ASGCT. Who would have guessed a short time afterwards Juno and Celgene would sign a 10 year collaboration?

June 30, 2015

Future of Prostate Cancer Immunotherapy

ASCO 2015 interview with Dr James Gulley from NCI on Prostate Cancer Immunotherapy.

June 29, 2015

Checkpoint inhibitors show early promise in Small Cell Lung Cancer

We've heard a lot about checkpoint immunotherapies in non-small cell lung cancer (NSCLC), but what about it's deadlier cousin, small cell lung cancer (SCLC)? Find out more...

June 16, 2015

Beyond the Big Four in checkpoint blockade

Beyond the Big Four in checkpoint inhibitors, there is a raft of other companies anxious to get in the action. We take a look at Merck Serono and their progress with avelumab, an anti-PDL1 antibody

June 11, 2015

Combined checkpoint inhibition and chemotherapy – useful or not?

How do we help patients who are non-responders or have stable disease respond to checkpoint inhibitors? Will chemotherapy combos help or not?

June 8, 2015

Highlights of Day 4 at ASCO 2015 Annual Meeting

Highlights from Monday at the 2015 ASCO annual meeting in Chicago

June 1, 2015

ASCO 2015 Highlights of Day 3

What's hot on Plenary Sunday at ASCO 2015? We'll be updating this blog post during the day.

May 31, 2015

Highlights of ASCO 2015 Day 2 Live Blog

Highlights from Day 2 at ASCO 15 in Chicago

May 30, 2015

ASCO 2015 Cancer Immunotherapy – Reflections on Day 1

Reflections on data presented in the first cancer immunotherapy press briefing at ASCO 2015

May 30, 2015

Suicide Genes – what are they and are they really needed?

Do you need to incorporate a suicide suicide switch into CAR T cells that allows you to turn off the response, force the T cells to self-destruct?

May 28, 2015

New therapies for multiple myeloma may make an impact

Data at ASGCT and ASCO highlight potential new treatments in development for multiple myeloma

May 18, 2015

AUA 2015 Update on bladder cancer

Update on checkpoint inhibitors in urothelial bladder cancer from AUA 2015 and what's in store for new developments with this disease.

May 15, 2015

Highlights of ASCO15 Abstracts – Preview No 1

First in a series of previews of ASCO 2015 annual meeting abstracts.

May 13, 2015

Tom Gajewski takes the STING out of Cancer

Dr Tom Gajewski is working on STING agonists that may have a major role to play in cancer immunotherapy.

May 13, 2015

Promise of Cancer Immunotherapy highlighted at Immunology 2015

At the 2015 annual meeting of the American Association of Immunologists (AAI) in New Orleans, leading experts shared their insights on the “Promise of Cancer Immunotherapy."

May 11, 2015

Top 10 immunotherapy studies with checkpoint blockade at ASCO 2015

What are the hot checkpoint studies to watch out for at ASCO 2015? We created a cheat sheet to follow and track the data as tsunami hits...

May 8, 2015

What happens when you combine checkpoint blockade with an immune stimulant in cancer?

What happens when we combine a checkpoint with an immune stimulant in advanced melanoma?

May 6, 2015

AACR Gems from the Poster Halls in ImmunoOncology

Beyond monotherapy with checkpoint inhibition, what combinations or sequences might be useful to explore next?

April 28, 2015

Where are checkpoint inhibitors going next?

Beyond lung cancer and melanoma, what other tumour types represent the low hanging fruit for checkpoint monotherapy?

April 24, 2015

Is this the end of ipilimumab in melanoma?

As the anti-PD-1 blockers show superiority in front-line metastatic melanoma, is this the end for Yervoy?

April 23, 2015

Top 10 Highlights of AACR 2015

The annual meeting of the American Association for Cancer Research ended today. Find out what were our top 10 highlights.

April 22, 2015

Checkpoint Inhibitor Data Rocks AACR 2015

Checkpoint Inhibitor data is a hot topic at AACR 2015. Data showed they may work in TNBC and also two checkpoints are better than one.

April 21, 2015

Reflections on AACR 2015 Cancer Immunotherapy Data

Cancer Immunotherapy is one of the hot topics at the 2015 AACR annual meeting in Philadelphia.

April 20, 2015

Anti-CTLA4 blockade with ipilimumab may be effective in hematologic malignancies

Does checkpoint blockade with CTLA4 have a role to play in hematologic malignancies?

April 15, 2015

UCL Drives CD19 CAR T Cell Therapy Forward in Europe

University College London (UCL) is leading the way in European clinical trials of CAR T Cell therapies that target CD19.

April 14, 2015

Novel Combination Approaches with Checkpoint Inhibitors

Emerging data on different combinations with checkpoint inhibitors suggests that this may increase response rates and outcomes for cancer patients. Find out more...

March 31, 2015

What is STING and why does it matter in cancer immunotherapy?

Novartis have announced a deal with Aduro Biotech for access to their STING-targeted CDN platform technology.

March 30, 2015

How do we improve responses to checkpoint inhibitors in lung cancer?

The mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

March 26, 2015

Will CAR-T cells make an impact in solid tumours?

Novel targets are emerging in urothelial bladder cancer which may offer new therapeutic options for antibody and CAR-T cell therapy development.

March 25, 2015

What would Charles Darwin make of renal cell carcinoma?

Why is renal cell carcinoma so challenging from a clinical and sequencing perspective?

March 23, 2015

Cellular therapy with EBV-CTL reduces death post stem cell transplant

What is the potential of a new cell therapy with cytotoxic T lymphocytes against Epstein Barr Virus (EBV-CTL)?

March 20, 2015

Emerging new biomarker for predicting checkpoint inhibitor responders

Predictive biomarkers of response will be key to reimbursement of immunotherapies in Europe. One is potentially emerging for ipilimumab (Yervoy), which may be useful in speeding up access.

March 19, 2015

AACR 2015 Cancer Immunotherapy Preview

What are the emerging new trends in cancer immunotherapy? Beyond monotherapy lies many combination opportunities yet to be explored. At AACR in April, we will see a raft of novel approaches being discussed.

March 11, 2015

How to enhance checkpoint inhibitors in hematologic malignancies

Will checkpoint inhibitors make an impact in hematologic malignancies or will novel combinations be needed?

March 4, 2015

How to make non-immunogenic cancers sensitive to checkpoint inhibitors

Not all cancers respond to checkpoint inhibitors - how can we change that situation? Here's one example, using prostate cancer as a model...

March 2, 2015

CAR-T and Gene Therapy excite BMT Tandem Meeting

Dr Krishna Komanduri discusses some of the best abstracts at the 2015 BMT Tandem meeting in San Diego.

February 25, 2015

CAR-T Cell Therapies from China are a Competitive Threat

Cellular Biomedicine Group (NASDAQ: CBMG) has acquired rights to the Chimeric Antigen Receptor T cell (CAR-T) therapy of the PLA General Hospital in Beijing.

February 11, 2015

The application of TILs, CARs and TCRs in cancer research

What does the evolving landscape for CAR, TIL and TCR cell therapies look like?

February 10, 2015

Tumour infiltrating lymphocytes TILs: what are they and why do they matter?

The NCI have been at the forefront of developing novel cancer immunotherapies for several decades, but what is the current status of their groundbreaking work? Find out more in this primer on TILs.

February 5, 2015

Bellicum moves BPX-501 T Cell Therapy forward $BLCM

What's the vision for Bellicum Pharmaceuticals? In an in-depth interview CEO Tom Farrell and COO Annemarie Moseley discuss the benefits offered by their new products in development.

January 13, 2015

Next generation approaches to immuno-oncology – where next?

What's next in immuno-oncology: what are potential ways to tackle the patients who do not respond to checkpoint immunotherapy?

January 8, 2015

Cellectis ramps up CAR-T development in 2015

What makes the Cellectis Chimeric Antigen Receptor CAR-T cell therapy different and what are the milestones expected in 2015?

January 6, 2015

Targeting the unmet medical need in GvHD

Graft versus Host disease (GvHD) is an area of tremendous unmet medical need that is triggering the interest of a number of biotech and rare disease companies.

January 5, 2015

Do Checkpoint Inhibitors work in Triple Negative Breast Cancer?

There is a lot of interest in checkpoint inhibitors, do they look they will be effective in Triple Negative Breast Cancer?

December 10, 2014

ASH 2014 Day 3 Live blog #ASH14

"Manic Monday" at the annual meeting of the American Society of Hematology features multiple oral sessions run at the same time!

December 8, 2014

ASH 2014 Day 2 Live Blog #ASH14

Coverage of Day 2 of the annual meeting of the American Society of Hematology in San Francisco.

December 7, 2014

ASH 2014 Day 1 Live Blog #ASH14

It's Day 1 of the 2014 annual meeting of the American Society of Hematology meeting in San Francisco.

December 6, 2014

ASH 2014 Annual Meeting Multiple Myeloma Preview

ASH 2014 Multiple Myeloma data looks like it offers much promise for new treatments as well as an increasingly competitive marketplace

December 2, 2014

The Science of PD1 PDL1 Cancer Immunotherapy

The science of targeting PD-1 and it's ligand PD-L1 in cancer immunotherapy is highlighted in five Letters published in Nature this week.

November 26, 2014

Targeting CD40 in Cancer Immunotherapy

How can we jumpstart the immune system to enable more patients to respond? At SITC we learned more about targeting CD40 to achieve this.

November 20, 2014

Can you reduce Graft versus Host Disease GvHD by regulating gut bacteria?

At the SITC 2014 annual meeting, Dr van den Brink presented data on how the bacteria in our gut (the intestinal microbiome) can impact GvHD.

November 18, 2014

Challenge of Cytokine Release Syndrome in CD19 CAR-T Cell Therapy

At the Society for Immunotherapy of Cancer (SITC) meeting last week, one of the Hot Topic sessions that took place after the conference formally ended was in managing the toxicities associated with chimeric antigen receptor T cell (CAR-T) therapy.

November 17, 2014

Will combining anti-OX40 with a checkpoint inhibitor matter in cancer?

OX40 could be an exciting new target in immune-oncology that could be combined with checkpoint inhibitors to improve the T cell response.

November 11, 2014

SITC 2014 Cancer Immunotherapy Day 1

Reflections on Day 1 of the 2014 annual meeting of the Society for Immunotherapy of Cancer (SITC).

November 8, 2014

SITC 2014 Cancer Immunotherapy Workshop Review

Day 1 of the SITC annual meeting started with two workshops on immunotherapy and combination therapy

November 7, 2014
Washington DC in Fall

SITC 2014 Cancer Immunotherapy Annual Meeting Preview

This week sees the start of the 2014 annual meeting of the Society for Immunotherapy of Cancer (SITC) at National Harbor, MD. We’re excited to be attending this meeting for the first time.

November 4, 2014

Immuno-Oncology Gems in the ESMO Poster Halls

There was a lot going on in lung, melanoma, renal and colorectal cancer in terms of immunotherapy in Madrid.

November 3, 2014

Update on PD1 checkpoint inhibition in lung cancer

Merck announced their Breakthrough therapy designation for Keytruda in lung cancer this morning. What did we learn from the updated data for checkpoint inhibitors in NSCLC at ESMO that was different from ASCO?

October 27, 2014

New therapies are emerging for the treatment of advanced stomach cancer

Checkpoint inhibitors are looking very promising in advanced gastric cancer

October 23, 2014

Breathing New Life into Bladder Cancer Treatment

At ESMO 2014, phase 1 clinical trial data in bladder cancer was presented for Pembrolizumab (Merck) and MPDL3280A (Roche/Genentech).

October 22, 2014

Potential of IDO as Immunotherapy Target

Genentech and NewLink announced a deal to license an IDO inhibitor. What's the impact of this on the IO pipeline?

October 20, 2014

ESMO 2014 Cancer Congress Day 3 Live Blog

Day 3 of the live blog from the ESMO 2014 Cancer Congress in Madrid.

September 28, 2014

ESMO 2014 Live Blog Day 2 #ESMO14

Day 2 Live Blog with news and commentary on what's taking place at the ESMO Cancer Congress in Madrid

September 28, 2014

ESMO 2014 Cancer Congress Day 1 Live Blog

ESMO 2014 Cancer Congress data starts to roll out today - throughout the day we'll be updating the blog with initial impressions of data as it's presented.

September 27, 2014

ESMO 2014 Takes Off with Release of Oral Abstracts #ESMO14

Most of the abstracts for oral presentations at the forthcoming ESMO cancer congress in Madrid have just been released. This is a preview of some that caught my attention.

September 24, 2014

ESMO 2014 Scientific Symposia Preview

There are some interesting science symposia at #ESMO14 in both immunotherapy and targeted therapies. We review what the hot topics are here.

September 19, 2014

ESMO 2014 Poster Preview

A review of the key poster and poster discussion abstracts on immunotherapy and targeted therapies at ESMO 2014

September 18, 2014

ESMO 2014 Preview: Immuno-oncology

Update on what to watch out for in immunotherapy at ESMO 2014.

September 16, 2014

What impact will nivolumab & pembrolizumab have on advanced melanoma?

How will we decide which therapies to give patients with metastatic melanoma once the new immunotherapies are available?

July 23, 2014
Cellectis CSO CEO

Can Cellectis Revolutionize CAR-T cell immunotherapy?

Cellectis is a Paris based biotechnology company with a “blue ocean” strategy that, if successful, could revolutionize cancer immunotherapy.

July 7, 2014

Kite Pharma Challenges and Opportunities Post-IPO $KITE

After it's successful IPO, what are some of the challenges and opportunities facing Kite Pharma and their CAR-T cell immunotherapy?

June 23, 2014

AstraZeneca MEDI4736 shows Immuno-Oncology promise at ASCO 2014

AstraZeneca showed impressive data at ASCO 2014 for MEDI4736, a new anti PD-L1 immunotherapy.

June 19, 2014

Making a difference in advanced bladder cancer

There have been no new therapies in urothelial bladder cancer for 30 years - until now...

June 17, 2014

ASCO 2014 Nivolumab vs Pembrolizumab in Metastatic Melanoma

PD-1 antibodies nivolumab and pembrolizumab show considerable promise in metastatic melanoma. At ASCO 2014 we learnt more about how they compare against each other and their potential as a backbone for combinations.

June 16, 2014

Combination strategies for nivolumab in Renal Cell Carcinoma

What does the ASCO 2014 data show when you combine checkpoint inhibitors nivolumab and ipilimumab?

June 13, 2014

6 important things I learned from AACR 2014 on immuno-oncology

Insights on checkpoint inhibitors, co-stimulants, CAR T cell therapy and bispecific antibody TCRs

May 2, 2014

New directions in immuno-oncology in biomarkers and combinations

Update on emerging potential immuno-oncology biomarkers and combinations from AACR

April 30, 2014

The real story behind Juno’s CAR T cell therapy suspensions

This weekend at AACR a controversy emerged on the safety of Juno's CAR T cell therapy.

April 6, 2014

Innate immunotherapy – is it ready for prime time in cancer research?

A review of innate immunotherapies including CD47, KIR, MICA and anti-glucan data at AACR in San Diego.

April 2, 2014

Will CAR T cells give new therapies for NHL and CLL a run for their money?

Much has been written about CAR T cells in B cell leukemias, but what about B cell lymphomas? Kite and the NCI had the honour of being the first to present data from ASH on their therapy in refractory DLBCL lymphomas

March 6, 2014

Update on immuno-oncology and biomarkers of response

ASCO GU saw an update on the ipilimumab study in post chemotherapy CRPC. New biomarker data published this week in melanoma may be potentially useful in prostate and other tumour types.

February 5, 2014

ASCO GU 2014 Optimal targeting of anti PD-1 and PD-L1 therapies in renal cancer

Update on progress with anti-PD1 and PD-L1 immunotherapies in renal cell cancer. Where is the field going in this space?

February 4, 2014

Update on anti-PD-L1 cancer immunotherapy

Roche Genentech are developing their anti-PD-L1 as both monotherapy and also in combination with targeted therapies in lung, melanoma, renal and colon cancers. How is the early development progressing?

January 22, 2014

ASCO GI Keynote: The future of Immunotherapy is Combinations

“We are at beginning of a REVOLUTION in immunotherapy,” said Elizabeth M. Jaffee, MD at the start of American Society of Clinical Oncology GastroIntestinal (ASCO GI) symposium keynote lecture on Immunologic Treatments for GI Cancers.

January 21, 2014

ASH 2013 Stunning ALL data with Novartis CTL019 CAR Therapy

UPenn and CHOP are using genetically modified chimeric antigen receptor (CAR) T cells to treat patients with B cell cancers such as ALL, B cell NHL, CLL and other B cell malignancies. At ASH, the impressive data from adult and pediatric ALL was presented. This post includes insights on this approach and an interview with Dr Stephan Grupp on the pediatric data.

January 9, 2014

New Immunotherapy data at IASLC Lung Cancer Meeting

Immunotherapy continues to be a hot topic in oncology with anti-PD-1 and other new approaches being discussed at the AACR-IASLC meeting in San Diego

January 7, 2014

Juno Therapeutics takes on Penn in dispute over St Jude Chimeric Antigen Receptor Patent

Start-up Juno Therapeutics is now in control of a legal dispute between St Jude Children’s Hospital and the University of Pennsylvania over chimeric antigen receptor (CAR) T cells intellectual property that contributed to the development of CTL019 licensed by Penn to Novartis. Penn are seeking to invalidate a St Jude patent that if upheld, CTL019 may infringe.

January 6, 2014

Juno Therapeutics takes on Novartis and seeks to revolutionize the treatment of blood cancers – an interview with Renier Brentjens

Juno Therapeutics is a start-up company with a mission to revolutionize the treatment of blood cancers through the use of chimeric antigen receptor (CAR) modified T cell therapy. The company recently launched with $120 million of series A funding. One of the scientific founders is Renier Brentjens MD, PhD, the Director of Cell Therapeutics at the Memorial Sloan-Kettering Cancer Center in NYC. He kindly gave an interview while at the ASH annual meeting in New Orleans.

December 13, 2013

Will anti-KIR immunotherapy make an impact in hematologic malignancies?

Immuno-oncology is a hot topic at the moment and many new targets are emerging that may be useful in combination. This post discusses Innate Pharma's anti-KIR program in hematologic malignancies.

December 12, 2013

ASH 2013 Preview: will new Seattle startup Juno Therapeutics push Novartis and U Penn in CART?

Chimeric Antigen Receptor T cell technology (CART) is an exciting new area, especially in hematologic malignancies. With the formation of a new start-up in Seattle, Juno Therapeutics, things just got very interesting...

December 4, 2013

New insights on checkpoint inhibitors and CART in CLL and solid tumors

An update on checkpoint inhibitors and CART from the AACR-NCI-EORTC Molecular Targets meeting - a lot of exciting possibilities are emerging!

October 25, 2013

ECCO Day 3: Update on alectinib, PD-L1, PI3K and MEK

Update on ALK (alectinib), PD-L1 (MEDI4736), PI3K (GDC-0980 and BKM120) and MEK (trametinib) inhibitors in solid tumours

September 30, 2013
ECCO 2013 Conference Amsterdam

A top line look at the PD-1 and PD-L1 abstracts at ECCO 2013

A quick review of the check point immunotherapy abstracts from #ECC2013 in Amsterdam.

September 19, 2013

How new approaches in targeted immunotherapy with anti-PD-1 and PD-L1 may change cancer research

Overview of anti-PD-1 and PD-L1 immunotherapies plus ASCO 2013 data in melanoma and lung cancer.

September 18, 2013

ASH 2012: CTL019 chimeric antigen receptor technology emerging as a new leukemia treatment

For many attendees, the most exciting news at the 2012 annual meeting of the American Society of Hematology (ASH) held last December in Atlanta was the prospect of personalized T cell therapy for the treatment of patients with B cell cancers such as chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL).

January 15, 2013